Pathological Gambling Clinical Trial
Official title:
Susceptibility to Pathological Gambling
Verified date | May 2023 |
Source | University of Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to assess the risk factors for the development of pathological gambling.
Status | Active, not recruiting |
Enrollment | 588 |
Est. completion date | November 2024 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 29 Years |
Eligibility | Inclusion Criteria: - Ability to understand the procedures and provide written consent - Gambled at least 5 times in the past year - Between the ages of 18 and 29 at intake Exclusion Criteria: - Inability to understand the procedures and provide written consent |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Structured Clinical Interview for Pathological Gambling (SCI-PG) | The SCI-PG is a validated and reliable scale assessing the presence of DSM-IV criteria for pathological gambling. The number of criteria met for PG is added for a total score and those meeting 5 or more criteria have DSM-IV pathological gambling.
Subjects are expected to be followed for the duration of the 3 year study. Diagnostic criteria for pathological gambling every 3 months for the length of the study |
Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02590211 -
Poker, Skills and Associated Problems
|
N/A | |
Completed |
NCT02203786 -
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
|
Phase 2 | |
Completed |
NCT05051085 -
Feasibility of the Internet-delivered Treatment "SpilleFri" for Patients With Pathological Gambling
|
N/A | |
Completed |
NCT01215357 -
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
|
Phase 2 | |
Terminated |
NCT00245583 -
Topiramate in the Treatment of Pathological Gambling
|
Phase 3 | |
Completed |
NCT04842461 -
Mental Health, Addictions and Biomarkers in High Athletes Performance
|
||
Not yet recruiting |
NCT03280966 -
Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder
|
Phase 2 | |
Active, not recruiting |
NCT01743092 -
Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment
|
N/A | |
Terminated |
NCT00211822 -
Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)
|
N/A | |
Completed |
NCT01381250 -
Effects of Internet-based Treatment of Pathological Gambling
|
N/A | |
Completed |
NCT05506384 -
Treatment Study for Problematic Gaming and Gambling
|
N/A | |
Enrolling by invitation |
NCT03464838 -
Effects of Transcranial Direct Current Stimulation (tDCS) in Gambling Disorder
|
N/A | |
Terminated |
NCT01560351 -
Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study
|
N/A | |
Completed |
NCT00580567 -
Impulsivity in Pathological Gambling
|
N/A | |
Completed |
NCT02240485 -
Integrative Couple Treatment for Pathological Gambling
|
N/A | |
Withdrawn |
NCT01340274 -
Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling
|
Phase 2 | |
Recruiting |
NCT02491996 -
The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers
|
N/A | |
Recruiting |
NCT01154712 -
Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling
|
Phase 1 | |
Completed |
NCT01843699 -
Topiramate Trial for Pathological Gamblers
|
Phase 2 | |
Completed |
NCT00927563 -
Tolcapone Treatment of Pathological Gambling
|
Phase 2 |